FDA Panel Says No to MDMA as Treatment for PTSD
WEDNESDAY, June 5, 2024 (HealthDay News) — A U.S. Food and Drug Administration advisory panel on Tuesday voted against recommending the psychedelic MDMA for the treatment of post-traumatic stress disorder (PTSD). In a 10-1 vote, the panel determined the evidence amassed so far fails to show the controversial drug’s benefitsContinue Reading










